Alvotech and Cipla have joined forces to bring biosimilars to treat oncology and autoimmune diseases to South Africa.
Reykjavik, Iceland-based Alvotech has partnered with Cipla Medpro to bring 5 biosimilar candidates to South Africa.
The portfolio will include 2 biosimilar candidates for oncology and 3 for autoimmune diseases; however, the 5 molecules that the biosimilars will reference were not publicly disclosed.
Alvotech will be in charge of development and supply of the products and Cipla will be responsible for commercialization and regulatory registration.
“We’re delighted to establish this important partnership with Cipla…an ideal commercial partner, with a leading presence in the South African pharmaceutical market,” Mark Levick, CEO of Alvotech, said in a statement.
Alvotech’s Other Partners
Alvotech does not have any biosimilars approved yet, but it has been setting other deals for biosimilar distribution with diverse business partners, possibly involving the same biosimilar candidates but in different geographic areas.
In September 2020, Alvotech extended its partnership with DKSH to include distribution of multiple biosimilar products in Asia, the United States, and Europe. Alvotech said this would involve distribution of an adalimumab biosimilar candidate (AVT02).
In August 2020, Alvotech announced a partnership with Teva Pharmaceuticals to commercialize 5 biosimilar candidates for the US market.
Additionally, Avotech has a partnership with JAMP Pharma to market 5 biosimilar candidates in the Canadian market and with Kamada for 6 biosimilar candidates in the Israeli market.
Except for AVT02, Alvotech and its partners have not disclosed any of the molecules included in the deals and there is no information on whether any of the candidates are the same between the deals.
More on Cipla Medpro
Cipla Medpro was founded in South Africa in 1995 under the name Enaleni Pharmaceuticals. Cipla Medpro mostly focuses on over-the-counter and generic medications.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.